Jafron Biomedical (stock code: 300529) unveiled its first-quarter report for 2024 at the close of April, highlighting significant financial achievements. During this period, the company achieved an operating income of $104.56 million USD, marking a substantial 30% increase compared to the same period last year. Furthermore, the net profit attributable to shareholders of the listed company stood at $40.08 million USD, reflecting an impressive year-on-year surge of 44.90%. Notably, sales revenue from various Hemoadsorption products soared to approximately $97.26 million USD, indicating a remarkable year-on-year increase of 85.51%.

Jafron attributed the robust performance in the first quarter to the gradual resolution of industry-specific challenges at the policy level. Over the past two years, the company has diligently implemented organizational restructuring, refined assessment methodologies, streamlined management processes, and conducted business operations aimed at enhancing efficiency and curbing costs. Consequently, these strategic initiatives have significantly bolstered the overall operational efficiency and management standards of the company.

In addition to its financial accomplishments, Jafron disclosed its profit distribution plan for the fiscal year 2023. The proposal entails issuing a cash dividend of 0.56 USD (tax included) per 10 shares to all shareholders, amounting to a total cash dividend payout of $43.6 million USD. This substantial dividend distribution, which represents approximately 70% of the company's net profit in 2023, underscores Jafron's commitment to rewarding its shareholders and signifies a noteworthy improvement in the company's cash flow dynamics.